US LNG exports surge but will buyers in China turn up?
CHICAGO - GE HealthCare Technologies Inc. (NASDAQ:GEHC) announced Tuesday that its Board of Directors has declared a quarterly cash dividend of $0.035 per share of common stock for the second quarter of 2025.
The dividend will be payable on August 15, 2025, to shareholders of record as of July 25, 2025, according to a company press release.
GE HealthCare, which describes itself as a global healthcare solutions provider, offers medical technology, pharmaceutical diagnostics, and AI-enabled solutions. The company operates through four business segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics.
The company reported annual revenue of $19.7 billion and employs approximately 53,000 people worldwide.
GE HealthCare was spun off from General Electric and began trading as an independent company on the Nasdaq stock exchange in January 2023. Discover more detailed insights and analysis in the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, GE HealthCare Technologies Inc. announced the issuance of $1.5 billion in senior unsecured notes, furthering its capital management strategy. The company has issued $650 million in 4.800% senior notes due January 15, 2031, and $850 million in 5.500% senior notes due June 15, 2035. Additionally, the U.S. Food and Drug Administration has approved an updated label for GE HealthCare’s Vizamyl, enhancing its capabilities in Alzheimer’s diagnosis and treatment monitoring. In analyst updates, BTIG reiterated a buy rating on GE HealthCare, citing the company’s stable growth trajectory in the medical imaging sector. The firm highlighted GE HealthCare’s consistent order growth and market expansion as positive indicators for future revenue. Furthermore, GE HealthCare has integrated its proprietary features with MIM Encore software, aiming to improve digital imaging and workflow solutions across various medical departments. The company also secured stockholder approval for executive compensation and the re-election of 10 directors during its recent annual meeting. These developments underscore GE HealthCare’s ongoing efforts in innovation and corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.